Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics

Core Insights - Amicus Therapeutics reported a revenue of $149.71 million for the quarter ended December 2024, reflecting a year-over-year increase of 30.1$0.09, a significant improvement from -$0.11 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate by 0.13$0.10 [1] Financial Performance Metrics - Geographic net product sales outside the U.S. were $87.26 million, which is 21.4$94.04 million [4] - U.S. geographic net product sales reached $62.44 million, exceeding the average estimate of$55.85 million and representing a 44.6% increase compared to the previous year [4] - Net product sales for Pombiliti and Opfolda totaled $22.21 million, slightly below the average estimate of$22.35 million [4] - Net product sales for Galafold were reported at $127.50 million, which is lower than the average estimate of$140.98 million but shows a year-over-year increase of 19.6% [4] Stock Performance - Over the past month, shares of Amicus Therapeutics have returned +0.2%, while the Zacks S&P 500 composite increased by +2.6% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]